Mauro Berrettini

Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT)

Gualtiero Palareti, Nicoletta Leali, S Coccheri et al. · The Lancet · 1996 · 1.3K citations

Thrombosis, Venous Thrombosis, Cardiovascular Disease +14

A randomized clinical trial of high‐intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)

Guido Finazzi, Roberto Marchioli, Vincenzo Brancaccio et al. · Journal of Thrombosis and Haemostasis · 2005 · 582 citations · Full text

Thrombosis, Randomized Clinical Trial, Cardiovascular Disease +7

Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: A four-year prospective study from the italian registry

Guido Finazzi, Vincenzo Brancaccio, Marco Moia et al. · The American Journal of Medicine · 1996 · 435 citations

Thrombosis, Venous Thrombosis, Cardiovascular Disease +13

Thrombotic events during oral anticoagulant treatment: results of the inception-cohort, prospective, collaborative ISCOAT study: ISCOAT study group (Italian Study on Complications of Oral Anticoagulant Therapy).

Gualtiero Palareti, Cesare Manotti, Armando D’Angelo et al. · PubMed · 1997 · 114 citations

Relative Risk, Pharmacotherapy, Anticoagulation Levels +22

Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation.

Paolo Gresele, Stefania Momi, Mauro Berrettini et al. · Journal of Clinical Investigation · 1998 · 103 citations · Full text

Immunology, Pharmacotherapy, Thrombin-induced Thromboembolism +20